Integral Molecular, a Philadelphia antibody discovery company founded in 2001, is marking its 25th anniversary by combining its three core technologies to build its own pipeline of therapeutic antibodies for cancer and other diseases, the company announced on November 12, 2026.
“We started Integral Molecular to solve scientific problems that were holding back drug discovery against membrane proteins implicated in some of the hardest-to-treat diseases,” said Benjamin Doranz, PhD, Co-Founder and CEO of Integral Molecular.
From Incubator to Industry Supplier
Drs. Benjamin Doranz, Joseph Rucker, and Sharon Willis founded Integral Molecular in 2001 in the University City Science Center’s incubator. The company started by developing technologies and services for other drug developers, and its tools are now used by more than 600 biotechnology and pharmaceutical organizations worldwide.
It has since moved into building its own therapeutic antibody pipeline. Its discoveries advance through licensing and partnerships, including CTIM-76, an out-licensed antibody now in clinical testing for solid tumors. The company is pursuing more than 100 disease-associated membrane proteins that have been difficult to target.
Three Technologies, One Pipeline
Many human proteins remain unexplored as drug targets because of complex biology and a lack of research tools, even when evidence links them to disease. Integral Molecular is combining three of its technologies to go after them.
Its subsidiary Cell Surface Bio generates antibodies against membrane proteins that have resisted other approaches. Paratope-PLUS® pairs the company’s CDR-Scanning technology with AI-assisted antibody engineering to find antibody variants with improved properties. The Membrane Proteome Array™ screens for unintended binding to other human proteins, which helps developers catch safety problems before a drug reaches the clinic and supports regulatory filings.
“Over 25 years, we’ve built the tools and expertise to tackle increasingly challenging targets,” Doranz said. “What excites us now is putting those capabilities together to discover potential new medicines against targets that have long been out of reach.”
Rooted in Philadelphia
Integral Molecular continues to expand in the city, investing in research facilities, scientific talent, and career development. Its community partnerships include the Wistar Institute, Drexel University, and the Science Center’s FirstHand program, which brings hands-on science to Philadelphia students. The City of Philadelphia has named the company an Employer of Choice, and The Philadelphia Inquirer has named it a Top Workplace.
“Philadelphia helped make Integral Molecular possible, and our people and community have been central to our success,” said Sharon Willis, PhD, Co-Founder. “As we continue to grow, we’re excited about the science ahead and the opportunities we’re creating to make an impact on patients and our community.”
About Integral Molecular
Integral Molecular develops technologies for discovering antibody therapeutics against difficult protein targets. Its 25 years of work has focused on membrane proteins, viruses, and antibodies, supporting drug discovery for cancer, diabetes, autoimmune disorders, and viral threats including SARS-CoV-2, Ebola, Zika, and dengue.
Source: Integral Molecular, https://www.prnewswire.com/news-releases/integral-molecular-celebrates-25-years-of-advancing-drug-discovery-as-a-cornerstone-of-philadelphias-biotech-community-302937031.html on November 12, 2026. Republished with credit to the original author. Read the original article.
Press Contact
Integral Molecular
Soma Banik, PhD
Director of Public Relations
215-966-6061
[email protected]